Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its holdings in Teva Pharmaceutical Industries by 23.5%, selling 24,300 shares, leaving them with 79,268 shares valued at approximately $1.33 million.
• Several hedge funds, such as Ion Asset Management Ltd. and Duquesne Family Office LLC, increased their stakes in Teva, reflecting a mixed sentiment among institutional investors with 54.05% of the stock owned by them.
• Analysts have a consensus rating of "Buy" for Teva, with target prices recently raised to $26.00 by major firms like JPMorgan and UBS, suggesting optimism about the company's growth potential.

Public Employees Retirement System of Ohio reduced its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 23.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,268 shares of the company's stock after selling 24,300 shares during the period. Public Employees Retirement System of Ohio's holdings in Teva Pharmaceutical Industries were worth $1,329,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Ion Asset Management Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock worth $599,945,000 after acquiring an additional 2,383,500 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its stake in Teva Pharmaceutical Industries by 2.8% during the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after acquiring an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after acquiring an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after buying an additional 22,044,407 shares in the last quarter. Finally, Duquesne Family Office LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 65.4% in the 1st quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock worth $228,702,000 after acquiring an additional 5,882,350 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Saturday, September 27th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research report on Friday. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $25.57.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $20.01 on Friday. The company has a market capitalization of $22.94 billion, a P/E ratio of -125.03, a price-to-earnings-growth ratio of 1.17 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The business has a 50-day simple moving average of $18.12 and a two-hundred day simple moving average of $16.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the previous year, the business earned $0.61 EPS. The company's quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.